Company intelligence / Profile preview

Unicorn Atlas

London, United Kingdomtheunicornatlas.com ↗

Ownership: Private
Development stage: Other

Overview

Unicorn Biotechnologies develops modular automated systems to industrialize mammalian cell production. Their technology reduces labor by over 80%, variability by over 50%, and production costs by 25–50%. The company targets both near-term revenue through licensing engineered cell lines and longer-term growth via “Cell-manufacturing-as-a-Service” offerings. They serve customers in cell/gene therapy, pharma R&D/manufacturing, and cellular agriculture/cultivated meat sectors. No clinical results are reported as they do not develop therapeutics themselves.

Modalities: Cell therapyGene therapyCultivated meat/cellular agriculture platforms
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Unicorn Atlas.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Unicorn Atlas.

Explore the full profile